Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Levodopa · Inbrija, NSC-118381

Small molecule · Agonist · developed by Merz Pharmaceuticals, Llc

Approved FDA
1 Registered trials

What is Levodopa?

Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier and is converted to dopamine in the brain, where it stimulates dopaminergic receptors. It is administered with carbidopa, a decarboxylase inhibitor that acts peripherally.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Inbrija, NSC-118381, V-1512, L-Dopa
Drug type
Small molecule
Mechanism
Agonist
Pathways
dopamine synthesis, dopaminergic signaling
Therapy area
Neurology
Developer
Merz Pharmaceuticals, Llc
In trials of
PTCT
FDA status
Approved as Inbrija, NDA209184 · FDA label
UNII
46627O600J

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07614126 N/A CTNNB1 Recruiting PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CTNNB1L-DOPA

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.